A Multicenter Phase 3 Randomized, Open-label Study Of Bosutinib Versus Imatinib In Adult Patients With Newly Diagnosed Chronic Phase Chronic Myelogenous Leukemia

Trial Profile

A Multicenter Phase 3 Randomized, Open-label Study Of Bosutinib Versus Imatinib In Adult Patients With Newly Diagnosed Chronic Phase Chronic Myelogenous Leukemia

Active, no longer recruiting
Phase of Trial: Phase III

Latest Information Update: 19 Jul 2018

At a glance

  • Drugs Bosutinib (Primary) ; Imatinib
  • Indications Chronic myeloid leukaemia
  • Focus Adverse reactions; Registrational; Therapeutic Use
  • Acronyms BFORE
  • Sponsors Avillion; Pfizer
  • Most Recent Events

    • 17 Jun 2018 Results of pooled data from two phase 3 trials (BFORE and BELA), were presented at the 23rd Congress of the European Haematology Association.
    • 17 Jun 2018 Results presented at the 23rd Congress of the European Haematology Association
    • 05 Jun 2018 24-month follow-up results, presented at the 54th Annual Meeting of the American Society of Clinical Oncology
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top